Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna
, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K. Warma, Opexa’s President and Chief Executive Officer, will deliver a corporate presentation at the Rodman & Renshaw Annual Global Investment Conference. The conference will be held September 8-10
at The Millennium Broadway Hotel in New York City.
Opexa’s presentation will occur at
2:50 p.m. (EDT) on Tuesday, September 10, 2013 in Room 7.04 of The Millennium Broadway Hotel
and will include an overview of the Company’s ongoing clinical development program for Tcelna, the Company’s lead therapy for MS. The presentation will be webcast and the link to access the audio webcast and presentation will be available on the Investor Relations page of the Company’s website at
Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders. The Company’s leading therapy candidate, Tcelna
, is a personalized T-cell immunotherapy currently in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Tcelna is derived from T-cells isolated from the patient’s peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin.
About Multiple Sclerosis (MS)
Multiple Sclerosis is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million people have MS worldwide.
While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common. The Secondary Progressive form of MS represents about a third of the MS patient population.